

Conclusion of Impression's Agreement with ONE Championship

Following an earlier announcement by Impression Healthcare Limited (“IHL” or “Impression”) on 2 August 2019 of the collaboration agreement with Group One Holdings Pte Ltd (trading as ONE Championship), for the provision of marketing of Gameday Mouthguards across ONE Championship's digital and physical infrastructure, Impression announces that the parties have mutually agreed to terminate the agreement.

Impression and ONE Championship have made this decision together due to a divergence in each of their respective strategic directions. The agreement has been terminated effective immediately.

Joel Latham, Managing Director and CEO of IHL said,

“We have a lot of respect for ONE Championship. That the parties have agreed that concluding the agreement is the best way forward to allow both companies to fully pursue their respective growth opportunities across all verticals, in no way alters this.

We don't envisage any material impact on the business resulting from the termination, given that the agreement was only in its very early stages. . Additionally, the termination will have no impact on our wider business strategy.”

IHL will deploy the break fee it is due to receive in connection with the termination and the fees that IHL would have paid under the agreement to IHL's pipeline of other growth initiatives. The Company does not consider these amounts to be material to its operations.

ENDS

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is an innovative healthcare company that sells customised oral devices both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network of dentists. With its own laboratory in Victoria, Australia, Impression offers best-in-class teeth-protection and helps its customers to combat bruxism, snoring, mild-to-moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression has broadened its commitment to disruption in the healthcare sector by progressing multiple opportunities in the field of medicinal cannabis. IHL has its licenses in place to import, export and distribute cannabis products. In March of 2019, Impression executed a binding collaboration with Cannvalate and Swinburne University of Technology to undertake four medicinal cannabis clinical trials. Cannvalate is Australia's largest distributor of medicinal cannabis products.

IHL also has a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated; a license agreement with Resolution Chemicals for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand; and also intends to distribute medicinal cannabis oils through the Cannvalate network of cannabis medicine prescribers throughout Australia.

Investors: investors@impression.healthcare

Website: www.impression.healthcare